Pharmacogenetics of antiretrovirals

Antiviral Research

Volumn 85, Issue 1, 2010, Pages 190-200

  Tozzi, Valerio ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Antiretroviral therapy; HAART; HIV; Hypersensitivity reactions; Pharmacodynamics; Pharmacogenetics; Pharmacokinetics

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CYTOCHROME P450 2B6; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; GLUCURONOSYLTRANSFERASE 1A1; HLA B ANTIGEN; HLA DR ANTIGEN; INDINAVIR; LAMIVUDINE; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EXCRETION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG RESPONSE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; KIDNEY TUBULE DISORDER; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; LONG TERM CARE; METABOLIC DISORDER; NEPHROTOXICITY; PANCREATITIS; PATIENT CARE; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; VIRUS RESISTANCE;

ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZOXAZINES; DIDEOXYNUCLEOSIDES; GLUCURONOSYLTRANSFERASE; HIV INFECTIONS; HLA-A ANTIGENS; HLA-B ANTIGENS; HUMANS; NEVIRAPINE; OLIGOPEPTIDES; OXIDOREDUCTASES, N-DEMETHYLATING; PHARMACOGENETICS; PYRIDINES;

EID: 73549101090     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.09.001     Document Type: Review

References (90)

1. Alonso-Villaverde C., Coll B., Gomez F., Parra S., Camps J., Joven J., and Masana L. The Efavirenz induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. AIDS 19 (2005) 341-342
2. Anderson P.L., Kakuda T.N., and Lichtenstein K.A. The cellular pharmacology of nucleoside and nucleotide-analogue reverse transcriptase inhibitors and its relationship to clinical toxicities. Clin. Infect. Dis. 38 (2004) 734-753
3. Anderson P.L., Lamba J., Aquilante C.L., Schuetz E., and Fletcher C.V. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J. Acquir. Immune Defic. Syndr. 42 (2006) 441-449
4. Arnedo M., Taffè P., Sahli R., Furrer H., Hirschel B., Elzi L., Weber R., Vernazza P., Bernasconi E., Darioli R., Bergmann S., Beckmann J.S., Telenti A., Tarr P.E., and Swiss HIV Cohort Study. Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenet. Genom. 17 (2007) 755-764
5. Asensi V., Rego C., Montes A.H., Montes A.H., Collazos J., Carton J.A., Castro M.G., Alvarez V., Fernández C., Maradona J.A., and Valle-Garay E. IL-1beta (+3954C/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART) against lipodystrophic syndrome. Genet. Med. 10 (2008) 215-223
6. Baylor M.S., and Johann-Liang R. Hepatotoxicity associated with nevirapine use. J. Acquir. Immune Defic. Syndr. 35 (2004) 538-539
7. Busti A.J., Hali R.G., and Margolis D.M. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 24 (2004) 1732-1747
8. Canter J.A., Haas D.W., Kallianpur A.R., Ritchie M.D., Robbins G.K., Shafer R.W., Clifford D.B., Murdock D.G., and Hulgan T. The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenom. J. 8 (2008) 71-77
9. Carr A., Samaras K., Thorisdottir A., Kaufmann G.R., Chisholm D.J., and Cooper D.A. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353 (1999) 2093-2099
10. Chung W.H., Hung S.I., and Chen Y.T. Human leukocyte antigens and drug hypersensitivity. Curr. Opin. Allergy Clin. Immunol. 7 (2007) 317-323
11. Clay P.G. The abacavir hypersensitivity reaction: a review. Clin. Ther. 24 (2002) 1502-1514
12. Costarelli S., Torti C., Gatta L.B., Tinelli C., Lapadula G., Quiros-Roldan E., Izzo I., Castelnuovo F., Biasiotto G., Arosio P., and Carosi G. No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. J. Acquir. Immune Defic. Syndr. 46 (2007) 255-256
13. Department of Health and Human Services (DHHS), 2008. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. November 3, 2008. Available at: http://www.hivatis.org, accessed: May 16th, 2009.
14. Dieterich D.T., Robinson P.A., Love J., and Stern J.O. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin. Infect. Dis. 38 (2004) S80-S89
15. Eugen-Olsen J., Iversen A.K., Garred P., Koppelhus U., Pedersen C., Benfield T.L., Sorensen A.M., Katzenstein T., Dickmeiss E., Gerstoft J., Skinhøj P., Svejgaard A., Nielsen J.O., and Hofmann B. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS 11 (1997) 305-310
16. Fauvel J., Bonnet E., Ruidavets J.B., Ferrières J., Toffoletti A., Massip P., Chap H., and Perret B. An interaction between apoC-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 15 (2001) 2397-2406
17. Fellay J., Marzolini C., Meaden E.R., Back D.J., Buclin T., Chave J.P., Decosterd L.A., Furrer H., Opravil M., Pantaleo G., Retelska D., Ruiz L., Schinkel A.H., Vernazza P., Eap C.B., Telenti A., and Swiss HIV Cohort Study. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359 (2002) 30-36
18. Felley C., Morris M.A., Wonkam A., Hirschel B., Flepp M., Wolf K., Furrer H., Battegay M., Bernasconi E., Telenti A., and Frossard J.L. The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study. AIDS 18 (2004) 1521-1527
19. Foulkes A.S., Wohl D.A., Frank I., Puleo E., Restine S., Wolfe M.L., Dube M.P., Tebas P., and Reilly M.P. Association among race/ethnicity, APOC-III genotypes, and lipids in HIV-1-infected individuals on antiretrovirals therapy. PLos Med. 3 (2006) 337-347
20. Gatanaga H., Hayashida T., Tsuchiya K., Yoshino M., Kuwahara T., Tsukada H., Fujimoto K., Sato I., Ueda M., Horiba M., Hamaguchi M., Yamamoto M., Takata N., Kimura A., Koike T., Gejyo F., Matsushita S., Shirasaka T., Kimura S., and Oka S. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin. Infect. Dis. 45 (2007) 1230-1237
21. Gatanaga H., Yazaki H., Tanuma J., Honda M., Genka I., Teruya K., Tachikawa N., Kikuchi Y., and Oka S. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 21 (2007) 264-265
22. Gazzard B.G., and BHIVA Treatment Guidelines Writing Group. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 9 (2008) 563-608
23. Guardiola M., Ferré R., Salazar J., Alonso-Villaverde C., Coll B., Parra S., Masana L., and Ribalta J. Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T→C gene variation. Clin. Chem. 52 (2006) 1914-1919
24. Haas D.W., Bartlett J.A., Andersen J.W., Sanne I., Wilkinson G.R., Hinkle J., Rousseau F., Ingram C.D., Shaw A., Lederman M.M., Kim R.B., and Adult AIDS Clinical Trials Group. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin. Infect. Dis. 43 (2006) 783-786
25. Haas D.W., Ribaudo H.J., Kim R.B., Tierney C., Wilkinson G.R., Gulick R.M., Clifford D.B., Hulgan T., Marzolini C., and Acosta E.P. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18 (2004) 2391-2400
26. Haas D.W., Smeaton L.M., Shafer R.W., Robbins G.K., Morse G.D., Labbe L., Wilkinson G.R., Clifford D.B., D'Aquila R.T., De Gruttola V., Pollard R.B., Merigan T.C., Hirsch M.S., George Jr. A.L., Donahue J.P., and Kim R.B. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult AIDS Clinical Trials Group Study. J. Infect. Dis. 192 (2005) 1931-1942
27. Hajeer A.H., and Hutchinson I.V. Influence of TNF-alpha gene polymorphisms on TNF-alpha production and disease. Hum. Immunol. 62 (2001) 1191-1199
28. Hammer S.M., Eron J.J., Reiss P., Schooley R.T., Thompson M.A., Walmsley S., Cahn P., Fischl M.A., Gatell J.M., Hirsch M.S., Jacobsen D.M., Montaner J.S., Richman D.D., Yeni P.G., Volberding P.A., and International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA Panel. JAMA 300 (2008) 555-570
29. Hetherington S., Hughes A.R., Mosteller M., Shortino D., Baker K.L., Spreen W., Lai E., Davies K., Handley A., Dow D.J., Fling M.E., Stocum M., Bowman C., Thurmond L.M., and Roses A.D. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359 (2002) 1121-1122
30. Hetherington S., McGuirk S., Powell G., Cutrell A., Naderer O., Spreen B., Lafon S., Pearce G., and Steel H. Hypersensitivity reactions during therapy with the nucleoside reverse trancriptase inhibitor abacavir. Clin. Ther. 23 (2001) 1603-1614
31. Hoehe M.R., Timmermann B., and Lehrach H. Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics. Curr. Pharm. Biotechnol. 4 (2003) 351-378
32. Hughes A.R., Mosteller M., Bansal A.T., Davies K., Haneline S.A., Lai E.H., Nangle K., Scott T., Spreen W.R., Warren L.L., Roses A.D., and CNA30027 Study Team; CNA30032 Study Team. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5 (2004) 203-211
33. Hughes D.A., Vilar F.J., Ward C.C., Alfirevic A., Park B.K., and Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14 (2004) 335-342
34. Hulgan T., Haas D.W., Haines J.L., Ritchie M.D., Robbins G.K., Shafer R.W., Clifford D.B., Kallianpur A.R., Summar M., and Canter J.A. Mitochondrial haplogroups and peripheral neuropathy during antiretrovirals therapy: an adult AIDS clinical trials group study. AIDS 19 (2005) 1341-1349
35. Imaoka T., Kusuhara H., Adachi M., Schuetz J.D., Takeuchi K., and Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol. Pharmacol. 71 (2007) 619-627
36. Izzedine H., Hulot J.S., Villard E., Goyenvalle C., Dominguez S., Ghosn J., Valantin M.A., Lechat P., and Deray A.G. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J. Infect. Dis. 194 (2006) 1481-1491
37. Kallianpur A.R., Hulgan T., Canter J.A., Ritchie M.D., Haines J.L., Robbins G.K., Shafer R.W., Clifford D.B., and Haas D.W. Hemocromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS 20 (2006) 1503-1513
38. Keswani S.C., Pardo C.A., Cherry C.L., Hoke A., and McArthur J.C. HIV-associated sensory neuropathies. AIDS 16 (2002) 2105-2117
39. Lichtenstein K.A., Delaney K.M., Armon C., Ward D.J., Moorman A.C., Wood K.C., Holmberg S.D., and HIV Outpatient Study Investigators. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 32 (2003) 48-56
40. Littera R., Carcassi C., Masala A., Piano P., Serra P., Ortu F., Corso N., Casula B., La Nasa G., Contu L., and Manconi P.E. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 20 (2006) 1621-1626
41. Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R., MacDonald M.E., Stuhlmann H., Koup R.A., and Landau N.R. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 (1996) 367-377
42. Madeddu G., Bonfanti P., De Socio G.V., Carradori S., Grosso C., Marconi P., Penco G., Rosella E., Miccolis S., Melzi S., Mura M.S., Landonio S., Ricci E., Quirino T., and CISAI Group. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed. Pharmacother. 62 (2008) 6-11
43. Maher B., Alfirevic A., Vilar F.J., Wilkins E.G., Park B.K., and Pirmohamed M. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 16 (2002) 2013-2018
44. Mallal S., Nolan D., Witt C., Masel G., Martin A.M., Moore C., Sayer D., Castley A., Mamotte C., Maxwell D., James I., and Christiansen F.T. Association between presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359 (2002) 727-732
45. Mallal S., Phillips E., Carosi G., Molina J.M., Workman C., Tomazic J., Jägel-Guedes E., Rugina S., Kozyrev O., Cid J.F., Hay P., Nolan D., Hughes S., Hughes A., Ryan S., Fitch N., Thorborn D., Benbow A., and PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358 (2008) 568-579
46. Martin A.M., Nolan D., Gaudieri S., Almeida C.A., Nolan R., James I., Carvalho F., Phillips E., Christiansen F.T., Purcell A.W., McCluskey J., and Mallal S. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 4180-4185
47. Martin A.M., Nolan D., James I., Cameron P., Keller J., Moore C., Phillips E., Christiansen F.T., and Mallal S. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 19 (2005) 97-99
48. Marzolini C., Telenti A., Decosterd L.A., Greub G., Biollaz J., and Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15 (2001) 1192-1194
49. Marzolini C., Paus E., Buclin T., and Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 75 (2004) 13-33
50. Monaghan G., Ryan M., Seddon R., Hume R., and Burchell B. Genetic variation in bilirubin UPD-glucuronofyltransferase gene promoter and Gilbert's syndrome. Lancet 347 (1996) 578-581
51. Motsinger A.A., Ritchie M.D., Shafer R.W., Robbins G.K., Morse G.D., Labbe L., Wilkinson G.R., Clifford D.B., D'Aquila R.T., Johnson V.A., Pollard R.B., Merigan T.C., Hirsch M.S., Donahue J.P., Kim R.B., and Haas D.W. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet. Genom. 16 (2006) 837-845
52. Muñoz de Benito R.M., and Arribas López J.R. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone. Expert Rev. Anti Infect. Ther. 4 (2006) 523-535
53. Nolan D., Moore C., Castley A., Sayer D., Mamotte C., John M., James I., and Mallal S. Tumor necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 17 (2003) 121-123
54. Peyrieère H., Nicolas J., Siffert M., Demoly P., Hillaire-Buys D., and Reynes J. Hypersensitivity related to abacavir in two members of a family. Ann. Parmacother. 35 (2001) 1291-1292
55. Rauch A., Nolan D., Martin A., McKinnon E., Almeida C., and Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin. Infect. Dis. 43 (2006) 99-102
56. Ribaudo H.J., Haas D.W., Tierney C., Kim R.B., Wilkinson G.R., Gulick R.M., Clifford D.B., Marzolini C., Fletcher C.V., Tashima K.T., Kuritzkes D.R., Acosta E.P., and Adult AIDS Clinical Trials Group Study. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin. Inf. Dis. 42 (2006) 401-407
57. Ritchie M.D., Haas D.W., Motsinger A.A., Donahue J.P., Erdem H., Raffanti S., Rebeiro P., George A.L., Kim R.B., Haines J.L., and Sterling T.R. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse transcriptase inhibitor hepatotoxicity. Clin. Inf. Dis. 43 (2006) 779-782
58. Robbins B., Srinivas R., Kim C., Bischofberger N., and Fridland A. Anti-human immunedeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA. Antimicrob. Agents Chemother. 42 (1998) 612
59. Rodriguez-Novoa S., Barreiro P., Rendón A., Barrios A., Corral A., Jiménez-Nacher I., González-Lahoz J., and Soriano V. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C/T polymorphism at the multidrug resistance gene 1. Clin. Infect. Dis. 42 (2006) 291-295
60. Rodriguez-Novoa S., Martin-Carbonero L., Barreiro P., González-Pardo G., Jiménez-Nácher I., González-Lahoz J., and Soriano V. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 21 (2007) 41-46
61. Rotger M., Colombo S., Furrer H., Bleiber G., Buclin T., Lee B.L., Keiser O., Biollaz J., Décosterd L., Telenti A., and Swiss HIV Cohort Study. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genom. 15 (2005) 1-5
62. Rotger M., Taffe P., Bleiber G., Gunthard H.F., Furrer H., Vernazza P., Drechsler H., Bernasconi E., Rickenbach M., Telenti A., and Swiss HIV Cohort Study. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. 192 (2005) 1381-1386
63. Rotger M., Tegude H., Colombo S., Cavassini M., Furrer H., Décosterd L., Blievernicht J., Saussele T., Günthard H.F., Schwab M., Eichelbaum M., Telenti A., and Zanger U.M. Predictive value of know and novel alleles of CYP2B6 for Efavirenz plasma concentrations in HIV-infected individuals. Clin. Pharmacol. Ther. 81 (2007) 557-566
64. Safrin S., and Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 13 (1999) 2493-2505
65. Saitoh A., Fletcher C.V., Brundage R., Alvero C., Fenton T., Hsia K., and Spector S.A. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516-T polymorphism. J. Acquir. Immune Defic. Syndr. 45 (2007) 280-285
66. Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M., Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G., Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y., Smyth R.J., Collman R.G., Doms R.W., Vassart G., and Parmentier M. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382 (1996) 722-725
67. Sanders F.A., Wheeler J.G., Myrand S.P., Lin C., Rubio J., Penny M., and the Maraviroc Team. Effect of CCR5 locus polymorphisms on virological response to maraviroc in antiretroviral-experienced individuals with CCR5-tropic HIV-1 in MOTIVATE 1 and 2. 11th European AIDS Conference. Madrid, Spain, 24-27 October 2007 (2007) (abstract P4.4/04)
68. Santos C.P., Felipe Y.X., Braga P.E., Ramos D., Lima R.O., and Segurado A.C. Self-perception of body changes in persons living with HIV/AIDS: prevalence and associated factors. AIDS 19 (2005) S14-S21
69. Schuetz J.D., Connelly M.C., Sun D., Paibir S.G., Flynn P.M., Srinivas R.V., Kumar A., and Fridland A. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5 (1999) 1048-1051
70. Syvanen A.C. Toward genome-wide SNP genotyping. Nat. Genet. 37 (2005) S5-S10
71. Taiwo B.O. Nevirapine toxicity. Int. J. STD AIDS 17 (2006) 364-370
72. Tarr P.E., Taffé P., Bleiber G., Furrer H., Rotger M., Martinez R., Hirschel B., Battegay M., Weber R., Vernazza P., Bernasconi E., Darioli R., Rickenbach M., Ledergerber B., Telenti A., and Swiss HIV Cohort Study. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J. Infect. Dis. 191 (2005) 1419-1426
73. Torno M.S., Witt M.D., Saitho A., and Fletcher C.V. Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature. Pharmacotherapy 28 (2008) 782-787
74. Tsuchiya K., Gatanaga H., Tachikawa N., Teruya K., Kikuchi Y., Yoshino M., Kuwahara T., Shirasaka T., Kimura S., and Oka S. Homozygous CYP2B6*6 (Q172h and K262R) correlates with high plasma efavirenz concentration in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun. 319 (2004) 1322-1326
75. van der Walt J.M., Nicodemus K.K., Martin E.R., Scott W.K., Nance M.A., Watts R.L., Hubble J.P., Haines J.L., Koller W.C., Lyons K., Pahwa R., Stern M.B., Colcher A., Hiner B.C., Jankovic J., Ondo W.G., Allen Jr. F.H., Goetz C.G., and Vance J.M. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am. J. Hum. Genet. 72 (2003) 804-811
76. van Leeuwen R., Lange J.M., Hussey E.K., Donn K.H., Hall S.T., Harker A.J., Jonker P., and Danner S.A. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 6 (1992) 1471-1475
77. Vitezica Z.G., Milpied B., Lonjou C., Borot N., Ledger T.N., Lefebvre A., and Hovnanian A. HLA-DRB1*0101 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 22 (2008) 540-541
78. Wallace D.C., Brown M.D., and Lott M.T. Mitochondrial DNA variation in human evolution and disease. Gene 238 (1999) 211-230
79. Wallace D.C. Mitochondrial DNA sequence variation in human evolution and disease. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 171-176
80. Wand H., Calmy A., Carey D.L., Samaras K., Carr A., Law M.G., Cooper D.A., Emery S., and INITIO Trial International Coordinating Committee. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 21 (2007) 2445-2453
81. Wang D., Johnson A.D., Papp A.C., Kroetz D.L., and Sadée W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variants 3455C>T affects mRNA stability. Pharmacogenet. Genom. 15 (2005) 693-704
82. Wang J., Sönnerborg A., Rane A., Josephson F., Lundgren S., Ståhle L., and Ingelman-Sundberg M. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet. Genom. 16 (2006) 191-198
83. Wenning L.A., Petry A.S., Kost J.T., Jin B., Breidinger S.A., DeLepeleire I., Carlini E.J., Young S., Rushmore T., Wagner F., Lunde N.M., Bieberdorf F., Greenberg H., Stone J.A., Wagner J.A., and Iwamoto M. Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin. Pharmacol. Ther. 85 (2009) 623-627
84. Westby M., and van der Ryst E. CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir. Chem. Chemother. 16 (2005) 339-354
85. Winzer R., Langmann P., Zylli M., Tollmann F., Schubert J., Klinker H., and Weissbrich B. No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment of naive HIV-positive patients. Ann. Clin. Microbiol. Antimicrob. 4 (2005) 3
86. Winzer R., Langmann P., Zylli M., Tollmann F., Schubert J., Klinker H., and Weissbrich B. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur. J. Med. Res. 8 (2003) 531-534
87. Wohl D.A., McComsey G., Tebas P., Brown T.T., Glesby M.J., Reeds D., Shikuma C., Mulligan K., Dube M., Wininger D., Huang J., Revuelta M., Currier J., Swindells S., Fichtenbaum C., Basar M., Tungsiripat M., Meyer W., Weihe J., and Wanke C. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin. Infect. Dis. 43 (2006) 645-653
88. Wyen C., Hendra H., Vogel M., Hoffmann C., Knechten H., Brockmeyer N.H., Bogner J.R., Rockstroh J., Esser S., Jaeger H., Harrer T., Mauss S., van Lunzen J., Skoetz N., Jetter A., Groneuer C., Fätkenheuer G., Khoo S.H., Egan D., Back D.J., Owen A., and German Competence Network for HIV/AIDS. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentration in HIV infected patients. J. Antimicrob. Chemother. 61 (2008) 914-918
89. Yasuda K., Matsunaga T., Adachi T., Aoki N., Tsujimoto G., and Tsuda K. Adrenergic receptor polymorphism and autonomic nervous system function in human obesity. Trends Endocrinol. Metab. 17 (2006) 269-275
90. Zanone Poma B., Riva A., Nasi M., Cicconi P., Broggini V., Cozzi Lepri A., Mologni D., Mazzotta F., D'Arminio Monforte A., Mussini C., Cossarizza A., Galli M., and the Icona Foundation Study Group. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. AIDS 22 (2008) 1769-1778